The in vitro effect of pirprofen on the surface ultrastructure and function of human platelets.
The in vitro effect of pirprofen (Rengasil), an antiinflammatory agent, on the surface ultrastructure and function of human platelets was examined and compared with that of acetylsalicylic acid (Aspirin, ASA), and diclofenac sodium (Voltaren, DS). Incubation with pirprofen induced formation of long, needle-shaped pseudopodia, a phenomenon observed also after incubation of the cells with DS. In contrast with ASA and DS, pirprofen induced a marked increase in platelet protein synthesizing capacity. The drug decreased the platelet aggregation to a degree similar to that of ASA and DS. The release of platelet factors 3 and 4 and the level of beta-thromboglobulin following incubation with the drug remained unaltered.
Djaldetti
M
M
Department of Medicine B, Hasharon Hospital, Petah-Tiqva, Tel Aviv University Medical School, Israel.
Gilgal
R
R
Creter
D
D
Zahavi
I
I
D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000648:ultrastructure*; D004008:Diclofenac / Q000494:pharmacology; D006801:Humans; D008855:Microscopy, Electron, Scanning; D010666:Phenylpropionates / Q000494:pharmacology*; D010977:Platelet Factor 3 / Q000378:metabolism; D010978:Platelet Factor 4 / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D010666:Phenylpropionates; D001620:beta-Thromboglobulin; D004008:Diclofenac; D010977:Platelet Factor 3; D010978:Platelet Factor 4; D001241:Aspirin; C008924:pirprofen